HIGHLIGHTS
SUMMARY
Because of these variabilities, discrepancies in the evaluation of treatment response during trials with double reads need to be monitored and, eventually, be adjudicated by a third reader. The authors investigated inter-reader variability in the original double read setting through a set of predefined disease-related quantitative and location features (double read-derived features shown in Table 2, disease locations listed in Annex A). Reader`s variability To further compare reader`s selections, the authors selected a subset of readers that evaluated 50 patients or more in two or more trials (i.e . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.